Kretschmer Alexander, Todenhöfer Tilman
Urologische Klinik und Poliklinik, Klinikum der Universität München, Ludwig-Maximilians-Universität, Marchioninistr. 15, 81377, München, Deutschland.
Studienpraxis Nürtingen, Steinengrabenstraße 17, 72622, Nürtingen, Deutschland.
Urologe A. 2020 Dec;59(12):1565-1576. doi: 10.1007/s00120-020-01381-9.
In recent years there have been substantial changes in the therapeutic landscape for systemic treatment of advanced prostate cancer (PCa), which resulted in a multitude of novel treatment options for different stages of the disease. In the current narrative review currently available treatment options for metastatic hormone-sensitive PCa as well as nonmetastatic castration-resistant PCa are presented. In addition, current treatment sequence options and targeted treatment in the stage of metastatic castration-resistant PCa are highlighted.
近年来，晚期前列腺癌（PCa）全身治疗的治疗格局发生了重大变化，这为该疾病的不同阶段带来了众多新的治疗选择。在本叙述性综述中，介绍了目前转移性激素敏感性PCa以及非转移性去势抵抗性PCa的可用治疗选择。此外，还重点介绍了转移性去势抵抗性PCa阶段目前的治疗顺序选择和靶向治疗。
